Abstract

The analysis and interpretation of high-throughput datasets relies on access to high-quality bioinformatics resources, as well as processing pipelines and analysis tools. Gene Ontology (GO, geneontology.org) is a major resource for gene enrichment analysis. The aim of this project, funded by the Alzheimer’s Research United Kingdom (ARUK) foundation and led by the University College London (UCL) biocuration team, was to enhance the GO resource by developing new neurological GO terms, and use GO terms to annotate gene products associated with dementia. Specifically, proteins and protein complexes relevant to processes involving amyloid-beta and tau have been annotated and the resulting annotations are denoted in GO databases as ‘ARUK-UCL’. Biological knowledge presented in the scientific literature was captured through the association of GO terms with dementia-relevant protein records; GO itself was revised, and new GO terms were added. This literature biocuration increased the number of Alzheimer’s-relevant gene products that were being associated with neurological GO terms, such as ‘amyloid-beta clearance’ or ‘learning or memory’, as well as neuronal structures and their compartments. Of the total 2055 annotations that we contributed for the prioritised gene products, 526 have associated proteins and complexes with neurological GO terms. To ensure that these descriptive annotations could be provided for Alzheimer’s-relevant gene products, over 70 new GO terms were created. Here, we describe how the improvements in ontology development and biocuration resulting from this initiative can benefit the scientific community and enhance the interpretation of dementia data.

Highlights

  • Understanding the cellular bases of Alzheimer’s disease (AD) and other dementias is an essential step in helping develop improved therapies for their treatment and prevention, as well9, 593 diagnosis

  • The gene products that were prioritised for Gene Ontology (GO) annotation were identified from two key reviews [41,42] and finalised following consultations with dementia experts

  • A collaboration was established with Complex Portal (CP) [14,63] biocurators, which resulted in the generation of 18 new CP entries for the different amyloid-beta monomers, dimers, and oligomers in three species (Table S2)

Read more

Summary

Introduction

Understanding the cellular bases of Alzheimer’s disease (AD) and other dementias is an essential step in helping develop improved therapies for their treatment and prevention, as well. 2 ofhave as supporting been identified [1], the majority of cases are likely to be due to multiple genetic, as well as environmental, 1. Introduction risk factors [2,3]. In order to understand the cellular processes and risk factors associated with AD. Understanding the cellular bases of Alzheimer’s disease (AD) and other dementias is an and other dementias, numerous transcriptomic, proteomic, and genome-wide association (GWA). Essential step in helping develop improved therapies for their treatment and prevention, as well as studies have been conducted [2,4,5,6]. Analyses andgenes the interpretation such high-throughput supporting early diagnosis

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.